Financial Analysis: Swedish Orphan Biovitrum (OTCMKTS:BIOVF) versus AbCellera Biologics (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for AbCellera Biologics and Swedish Orphan Biovitrum, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1	1	7	2	2.91
Swedish Orphan Biovitrum	0	3	5	0	2.62

AbCellera Biologics presently has a consensus target price of $16.20, suggesting a potential upside of 42.54%. Given AbCellera Biologics’ stronger consensus rating and higher possible upside, research analysts clearly believe AbCellera Biologics is more favorable than Swedish Orphan Biovitrum.

Insider & Institutional Ownership

61.4% of AbCellera Biologics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares AbCellera Biologics and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-218.54%	-15.35%	-10.84%
Swedish Orphan Biovitrum	20.67%	17.92%	9.30%

Valuation & Earnings

This table compares AbCellera Biologics and Swedish Orphan Biovitrum”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$67.85 million	51.35	-$146.41 million	($0.48)	-23.68
Swedish Orphan Biovitrum	$2.89 billion	6.30	$48.85 million	$2.01	25.40

Swedish Orphan Biovitrum has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

AbCellera Biologics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Summary

AbCellera Biologics beats Swedish Orphan Biovitrum on 8 of the 15 factors compared between the two stocks.

About AbCellera Biologics

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.